Locally Advanced Breast Cancer Clinical Trials

12 recruiting

Locally Advanced Breast Cancer Trials at a Glance

15 actively recruiting trials for locally advanced breast cancer are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Shanghai, Jinan, and Beijing. Lead sponsors running locally advanced breast cancer studies include Forward Pharmaceuticals Co., Ltd., BioNTech SE, and Austrian Breast & Colorectal Cancer Study Group.

Browse locally advanced breast cancer trials by phase

Treatments under study

About Locally Advanced Breast Cancer Clinical Trials

Looking for clinical trials for Locally Advanced Breast Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled17 locationsNCT07347600
Recruiting
Phase 1Phase 2

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Phase 1

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast
Calibr, a division of Scripps Research20 enrolled5 locationsNCT06878248
Recruiting
Phase 1Phase 2

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 3

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Metastatic Breast CancerLocally Advanced Breast Cancer
Shandong Suncadia Medicine Co., Ltd.240 enrolled2 locationsNCT07024173
Recruiting
Early Phase 1

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Breast CancerHER2-positive Breast CancerLocally Advanced Breast Cancer+1 more
Alison Stopeck30 enrolled1 locationNCT06220214
Recruiting
Phase 1Phase 2

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Not Applicable

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Early and Locally Advanced Breast Cancer
Austrian Breast & Colorectal Cancer Study Group350 enrolled14 locationsNCT07084558
Recruiting
Phase 3

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Locally Advanced Breast Cancer
RenJi Hospital316 enrolled1 locationNCT04254263
Recruiting

FDG PET-CT in Advanced Breast Cancer

Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment AvailableIf There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
Samsung Medical Center100 enrolled1 locationNCT07173868
Recruiting
Phase 2

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Breast CancerBreast Cancer Stage IBreast Cancer Stage II+5 more
UNC Lineberger Comprehensive Cancer Center90 enrolled1 locationNCT06727773
Recruiting

To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients

Locally Advanced Breast Cancer
Henan Cancer Hospital300 enrolled1 locationNCT06605521
Recruiting
Not Applicable

The Choice of Treatment Methods and Efficacy of LABC

Locally Advanced Breast Cancer
Peking Union Medical College Hospital50 enrolled1 locationNCT06080620
Recruiting
Phase 4

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast CancerHormone Receptor Positive,HER2-negative Breast Cancer
Yongsheng Wang100 enrolled1 locationNCT05809024